BioTrove Combines Forces with OSI Pharmaceuticals to Enable Lead Discovery
Complete the form below to unlock access to ALL audio articles.
BioTrove, Inc. has announced a new, non-exclusive marketing agreement with OSI Pharmaceuticals, Inc. to provide clients with a complete solution for lead compound discovery.
Combining OSI Pharmaceuticals’ Integrated Lead Discovery Platform with BioTrove’s RapidFire™ mass spectrometry-based assay development, screening and analysis services, the agreement will enable customers to pursue challenging drug targets in an accurate, efficient and cost-effective manner, BioTrove says.
“The collaboration addresses a critical, unmet need for companies in the biopharmaceutical industry, especially those without access to compound libraries or screening infrastructure,” said Albert A. Luderer, Ph.D., President and CEO, BioTrove. “Our joint solution with OSI will enable increased research around novel targets for companies who may have crucial insights about disease progression, but do not specialize in large-scale high-throughput screening internally.”
The companies’ complete lead discovery service will provide access to OSI Pharmaceuticals’ Integrated Lead Discovery Platform, enabling screening of large volumes of compounds against clients’ target assays. BioTrove’s mass spectrometry-based RapidFire platform, which enables label-free high-throughput screening using biological substrates, will be used to identify active compounds within chemical libraries.
“The synergistic combination of OSI’s Lead Discovery Platform with BioTrove’s RapidFire screening technology provides an innovative solution to early drug discovery, opening up a wide array of new targets for the biotechnology industry,” said David Ghesquiere, Vice President, Corporate and Business Development, OSI Pharmaceuticals, Inc.
Financial terms were not disclosed.
